Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 9524659

[Thyroid cancers].

V Mogoş·E Zbranca·V Strat·M R Diaconescu·M Chifan·N Florea·G Costăchescu·M R Găleşanu·V Rusu·G Georgescu
View original source ↗Export metadata ↓

Abstract

We have analysed factors that influenced on the patient survival in 195 cases of thyroid cancer. The survival is essentially influenced by the histology, the papillary forms (survival after 15 years: 83.1-93%) and follicular cancers (survival after 15 years: 84-94%) having an excellent evolution. The non-differentiated and mixed cancers have a very severe prognosis that is independent of the complex therapy that have been used (survival after 5 years: 17.1% in non-differentiated forms and 32.5% in mixed ones). The prognosis is better in subjects under the age of 45 and in female subjects. The cancers in the 1-st and 2-nd stage of tumor extension have a better evolution that those in the 3-rd stage. In differentiated cancers, the total or subtotal thyroidectomy followed by radioiodine administration determine the best survival.

Explore related subjects

Adenocarcinoma, FollicularAdultAge DistributionCarcinoma, MedullaryCarcinoma, PapillaryFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisRomaniaSex DistributionThyroid NeoplasmsThyroidectomyEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

V Mogoş, E Zbranca, V Strat, M R Diaconescu, M Chifan, N Florea, G Costăchescu, M R Găleşanu, V Rusu, G Georgescu. [Thyroid cancers].. https://pubmed.ncbi.nlm.nih.gov/9524659/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

[Small thyroid carcinomas: biological characteristics, diagnosis and therapy].

Small thyroid carcinomas (< or = 1.5 cm), including microcarcinomas (< or = 1.0 cm) (n = 39), were found in 53 patients (41%) with a papillary (n = 130) and in 4 cases (4%) with a follicular (n = 110) carcinoma. The tumour was clinically manifested by palpability or by the presence of nodal metastases in 1/3 of patients. Concomitant diagnoses were colloid goitre (n = 24), cellular adenoma (n = 11), Graves' disease (n = 6), and Hashimoto's thyroiditis (n = 4). Nodal involvement, multifocal tumour, and extrathyroidal extent (pT4) were present in 9%, 19%, and 8% of cases respectively. Small follicular carcinomas were minimally invasive in all instances. According to the age-related prognostic TNM-classification, 52 patients (91%) were in the low risk category. 18% of the patients underwent uni- or bilateral partial lobectomy, 35% hemithyroidectomy, and 47% total thyroidectomy, according to the extent and nature of the concomitant benign disease, whereas hemi- or total thyroidectomy was performed in the patients with known cancer. Four of 5 patients with stage pT4 cancer and all patients with nodal involvement underwent total thyroidectomy with radioiodine (n = 8 [14%]). Postoperative morbidity was 0%. During the follow-up period of 1-17 (x = 5.5) years no tumour-related death and no serious recurrence was noted. One node recurrence was removed 1 year following treatment of a stage III pT1aN1b papillary carcinoma; the patient died 4 years later accidentally without residual disease. These results confirm that cases with a potentially favourable course can be defined and treated selectively by less radical measures. Small carcinomas (< or = 1.5 cm) belong to these favourable tumours with a cancer mortality rate of virtually 0%, and the aim of treatment is to prevent curable recurrences: node positivity is an important risk factor, and therefore radioiodine is reserved for carcinomas with nodal involvement and also for the occasional small pT4-tumour.

Adenocarcinoma, Follicular↗
PubMed1999

Unusual features of thyroid carcinomas in Japanese patients with Werner syndrome and possible genotype-phenotype relations to cell type and race.

BACKGROUND: Werner syndrome (WS), an autosomal recessive disease characterized by premature aging, has a high frequency of association with six rare neoplasms in Japanese patients, and only four of these neoplasms also occur excessively in whites. Several differ from what is usual in their epidemiology and/or histology. Described in this article are peculiarities in the occurrences of follicular and papillary thyroid carcinomas among Japanese patients and the possible genotype-phenotype relations pertaining to cell types and the absence of excess thyroid carcinoma occurrence in whites with WS. METHODS: Epidemiologic features of 23 histologically diagnosed thyroid carcinomas from a series of 150 cancers in 845 Japanese patients with WS were compared with those of 19,446 tumors in a Japanese national registry of thyroid carcinomas from 1977-1991. Germline mutations had been determined by molecular studies of peripheral blood. RESULTS: The average age of patients with thyroid carcinoma was 39 years for those with WS and 49 years for the registry patients. The female-to-male ratios were 2.3:1 and 6.6:1, respectively. The rates of occurrence of papillary, follicular, and anaplastic carcinomas were 35%, 48%, and 13% for Japanese patients with WS and 78%, 14%, and 2% in the general Japanese population. All four cases of follicular carcinoma had germline mutations of the WS gene in the C-terminal region, and the germline mutation for the only papillary carcinoma was in the N-terminal region. CONCLUSIONS: This study suggests two possible WS genotype-phenotype relations. One concerns thyroid carcinoma histology; the other concerns frequent mutations that occur in the C-terminal region in Japanese patients, but not in white patients, with WS. These may account for the excess thyroid carcinoma occurrence among Japanese.

Adenocarcinoma, Follicular↗
PubMed1999

Surveillance of patients to detect recurrent thyroid carcinoma.

BACKGROUND: The purpose of this study was to evaluate the utility of surveillance with annual whole-body iodine-131 (131I) scintigraphy for patients with recurrent thyroid carcinoma. METHODS: The records of patients with thyroid carcinoma were reviewed. The 76 patients included in this study had undergone thyroidectomy and postoperative 131I therapy, and had at least 1 negative whole-body 131I scintigraphy 1 year after 131I therapy. There were 59 females and 17 males (age range, 12-74 years). Surgery consisted of a total thyroidectomy for 84% of patients and a subtotal thyroidectomy for 16%. 131I was administered within 1 month of thyroidectomy and annually thereafter until complete ablation of remaining thyroid tissue occurred. Annual follow-up diagnostic whole-body 131I scintigraphy was performed at Years 1 and 2, and then every 3-5 years. Some patients also had scintigraphy performed in Years 3, 4, and 5. RESULTS: Patients received 1-4 annual administrations of 131I (median, 1). The administered activity per treatment was 30-211 mCi, and the total activity administered that was necessary to achieve complete ablation of functioning thyroid tissue ranged from 30 to 514 mCi (median, 100 mCi). The relapse free survival at both 5 and 10 years was 88%. By definition, all of these patients had a negative 131I scintigraphy at 1 year after their last therapeutic 131I administration. Seven patients had a positive 131I scintigraphy 1 year after the first negative scintigraphy. Two other patients had positive 131I images after 2 consecutive negative annual 131I scintigraphic studies. The predictive value for relapse free survival of 1 negative diagnostic 131I study of these patients was 91% (+/- 0.02), and for 2 consecutive annual negative 131I studies the value was 97% (+/- 0.02); these results were significantly different (P = 0.0197). A stepwise logistic regression analysis was performed in an effort to identify risk factors for disease recurrence after complete ablation. None of the variables assessed--age, gender, tumor histology, tumor size, vascular invasion, capsular invasion, surgical margin status, or lymph node status--was predictive of recurrence after complete ablation. CONCLUSIONS: A single negative 131I scintigraphic study after complete ablation has a lower predictive value for relapse free survival than do two consecutive annual negative studies. Annual 131I imaging is recommended for surveillance until 2 consecutive annual negative studies are obtained, after which repeat imaging at 3-5 years appears to be satisfactory.

Adenocarcinoma, Follicular↗